Wai Yuen Tong Medicine Holdings (HKSE:00897) EBIT : HK$157 Mil (TTM As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Wai Yuen Tong Medicine Holdings EBIT?

Wai Yuen Tong Medicine Holdings's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2023 was HK$96 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was HK$157 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Wai Yuen Tong Medicine Holdings's annualized ROC % for the quarter that ended in Sep. 2023 was 1.31%. Wai Yuen Tong Medicine Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 10.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Wai Yuen Tong Medicine Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 11.43%.

Wai Yuen Tong Medicine Holdings EBIT Historical Data

The historical data trend for Wai Yuen Tong Medicine Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wai Yuen Tong Medicine Holdings EBIT Chart

Wai Yuen Tong Medicine Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

110.25

507.95

-195.41

48.39

94.37

Wai Yuen Tong Medicine Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBIT	Get a 7-Day Free Trial															102.17	-53.78	33.42	60.95	96.22

Competitive Comparison of Wai Yuen Tong Medicine Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wai Yuen Tong Medicine Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wai Yuen Tong Medicine Holdings's EV-to-EBIT falls into.

Wai Yuen Tong Medicine Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$157 Mil.

Wai Yuen Tong Medicine Holdings (HKSE:00897) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Wai Yuen Tong Medicine Holdings's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	133.366 * ( 1 - 45.03% )	/	( (5568.754	+	5646.33)	/ 2 )
=	73.3112902	/	5607.542
=	1.31 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7013.815	-	865.725	-	( 579.336	-	max(0, 1657.188	-	2702.37	+	579.336	))
=	5568.754

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6583.962	-	432.209	-	( 505.423	-	max(0, 1615.96	-	2526.045	+	505.423	))
=	5646.33

Note: The Operating Income data used here is two times the semi-annual (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Wai Yuen Tong Medicine Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	192.438	/	( ( (961.159 + max(810.261, 0))	+	(899.178 + max(889.497, 0)) )	/	2 )
=	192.438	/	( ( 1771.42	+	1788.675 )	/	2 )
=	192.438	/	1780.0475
=	10.81 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(68.028	+	1636.601	+	148.43)	-	(865.725	+	0	+	177.073)
=	810.261

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(66.566	+	1611.006	+	68.339)	-	(432.209	+	0	+	424.205)
=	889.497

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Wai Yuen Tong Medicine Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	157.165	/	1374.854
	=	11.43 %

Wai Yuen Tong Medicine Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Wai Yuen Tong Medicine Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Wai Yuen Tong Medicine Holdings (HKSE:00897) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wai Yuen Tong Medicine Holdings Ltd (HKSE:00897) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

39 Wang Kwong Road, Suite 3101, 31st Floor, Skyline Tower, Kowloon Bay, Kowloon, Hong Kong, HKG

Website

https://www.wyth.net

Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties in the agricultural produce market. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.

Executives

Wang On Group Limited	2501 Other
Tang Ching Ho	2501 Other
Yau Yuk Yin	2202 Interest of your spouse

Wai Yuen Tong Medicine Holdings (HKSE:00897) Headlines

No Headlines